Clinical trial
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With…
NCT00137969 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00137969 |
|---|---|
| Title | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus |
| Official title | Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With Moderate to Severe Systemic Lupus Erythematosus |
| Acronym | EXPLORER |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Lupus Erythematosus, Systemic |
| Intervention type | Drug |
| Interventions | Rituximab, Placebo, Prednisone, Acetaminophen, Diphenhydramine |
| Enrollment | 262 |
| Start date | May 10, 2005 |
| Primary completion | Aug 25, 2008 |
| Completion | Aug 25, 2008 |
| First posted | Aug 30, 2005 |
| Last update posted | Aug 20, 2019 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: